Bergen, Norway, 8 January 2026 - Lifecare ASA (LIFE) today announces a major
system-level milestone, reporting the first in-vivo confirmation that its
fully integrated implantable Continuous Glucose Monitoring (CGM) system
functions as intended, using implants from the company's first reproducibly
manufactured production batch.
In practical terms, this means Lifecare's implant has now been shown to track
glucose inside a living body using reproducibly manufactured implants, without
relying on laboratory conditions or external calibration.
The results were generated in Lifecare's ongoing longevity
study LFC-SEN-002 and represent the first real-life operation of the company's
complete implant architecture in living tissue, combining manufacturing
reproducibility, biological compatibility and system-level functionality in a
single in-vivo deployment.
First in-vivo operation of fully functional dual-cavity implant
The latest implantation marks the first in-vivo deployment of a fully
functional wireless dual-cavity implant, in which both the glucose-reactive
cavity and the reference cavity operate simultaneously in living tissue as
designed. The implant was produced, tested, sterilised and cleared for
implantation in December 2025 as part of Lifecare's first reproducibly
manufactured batch under the company's current production protocol.
This milestone represents a decisive transition from component-level and
laboratory validation to system-level execution in vivo, confirming that
Lifecare's implantable CGM system can be manufactured reproducibly and
function coherently in a real biological environment.
Raw in-vivo signals behave coherently without calibration or correction
Early data collected following implantation show that the implant
produces coherent and physiologically plausible signal behaviour in vivo. No
calibration, smoothing, filtering, or post-hoc correction has been applied.
Nevertheless, the raw sensor output demonstrates directional signal variations
consistent with changes in glucose levels, benchmarked against reference data
from a commercially available CGM system.
These observations are derived exclusively from unprocessed raw data. No
claims are made at this stage regarding numerical glucose accuracy, clinical
performance, or diagnostic use. The purpose of the current phase
of LFC-SEN-002 is to confirm system integrity, biological compatibility and
functional behaviour of the fully integrated implant architecture under
real-life conditions.
"This is the first time we see our full implant architecture operating over
time in vivo exactly as designed, using implants from our first reproducibly
manufactured batch," says Joacim Holter, CEO of Lifecare. "The observed signal
behaviour mirrors what we previously demonstrated in human proof-of-concept
results with wired sensors - now realised in a fully integrated, wireless
implant. This reconfirms the sensing principle in living tissue and marks a
clear transition from feasibility to optimisation and performance refinement."
Clear system confirmation; optimisation remains
The findings from this phase of LFC-SEN-002 confirm that:
* the implant architecture functions coherently in vivo,
* the sensing principle behaves as expected in a wireless living system, and
* the remaining development focus is on system optimisation, stability and
refinement.
The study continues to generate data supporting:
* further optimisation of system stability and signal isolation,
* preparation for veterinary market entry, and
* Lifecare's regulatory pathway towards first-in-human clinical studies and CE
marking.
About LFC-SEN-002
LFC-SEN-002 is an ongoing longevity and performance study evaluating
Lifecare's implantable CGM technology in dogs. The study focuses on
biocompatibility, system stability and in-vivo signal behaviour, and supports
both veterinary product development and future human clinical programs. The
study is conducted under veterinary supervision in cooperation with
the Faculty of Veterinary Medicine, Department of Companion Animal Clinical
Sciences at the Norwegian University of Life Sciences. Data generated in the
study provide direct input to Lifecare's ongoing development and execution
program.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42